Bumetanide oral solution for the treatment of children and adolescents with autism spectrum disorder: Results from two randomized phase III studies
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Bumetanide oral solution for the treatment of children and adolescents with autism spectrum disorder: Results from two randomized phase III studies
Authors
Keywords
-
Journal
Autism Research
Volume 16, Issue 10, Pages 2021-2034
Publisher
Wiley
Online
2023-10-06
DOI
10.1002/aur.3005
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The immuno-behavioural covariation associated with the treatment response to bumetanide in young children with autism spectrum disorder
- (2022) Qingyang Li et al. Translational Psychiatry
- A Phase III Study of Bumetanide Oral Liquid Formulation for the Treatment of Children and Adolescents Aged Between 7 and 17 Years with Autism Spectrum Disorder (SIGN 1 Trial): Participant Baseline Characteristics
- (2022) Christina Georgoula et al. CHILD PSYCHIATRY & HUMAN DEVELOPMENT
- Prediction of behavioral improvement through resting-state EEG and clinical severity in a randomized controlled trial testing bumetanide in autism spectrum disorder
- (2021) Erika L. Juarez-Martinez et al. Biological Psychiatry-Cognitive Neuroscience and Neuroimaging
- Pharmacological tools to target NKCC1 in brain disorders
- (2021) Annalisa Savardi et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Prevalence of Autism Spectrum Disorder and Co-morbidities in Children and Adolescents: A Systematic Literature Review
- (2021) Clémence Bougeard et al. Frontiers in Psychiatry
- Treatment Effect of Bumetanide in Children With Autism Spectrum Disorder: A Systematic Review and Meta-Analysis
- (2021) Tiantian Wang et al. Frontiers in Psychiatry
- Effects of bumetanide on neurodevelopmental impairments in patients with tuberous sclerosis complex: an open-label pilot study
- (2020) Dorinde M. van Andel et al. Molecular Autism
- Bumetanide for Core Symptoms of Autism Spectrum Disorder (BAMBI): A Single Center, Double-Blinded, Participant-Randomized, Placebo-Controlled, Phase Two, Superiority Trial
- (2020) Jan J. Sprengers et al. JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY
- The Autism Impact Measure (AIM): Examination of Sensitivity to Change
- (2020) Micah O. Mazurek et al. Autism Research
- The Association Between Somatic Health, Autism Spectrum Disorder, and Autistic Traits
- (2019) Pei-Yin Pan et al. BEHAVIOR GENETICS
- Bumetanide for autism: more eye contact, less amygdala activation
- (2018) Nouchine Hadjikhani et al. Scientific Reports
- Autism spectrum disorder: Consensus guidelines on assessment, treatment and research from the British Association for Psychopharmacology
- (2017) Oliver D Howes et al. JOURNAL OF PSYCHOPHARMACOLOGY
- NKCC1 Chloride Importer Antagonists Attenuate Many Neurological and Psychiatric Disorders
- (2017) Yehezkel Ben-Ari TRENDS IN NEUROSCIENCES
- Effects of bumetanide on neurobehavioral function in children and adolescents with autism spectrum disorders
- (2017) E Lemonnier et al. Translational Psychiatry
- Look me in the eyes: constraining gaze in the eye-region provokes abnormally high subcortical activation in autism
- (2017) Nouchine Hadjikhani et al. Scientific Reports
- The Long and Winding Road to Gamma-Amino-Butyric Acid as Neurotransmitter
- (2016) Massimo Avoli et al. CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES
- Pharmacologic Treatment of Severe Irritability and Problem Behaviors in Autism: A Systematic Review and Meta-analysis
- (2016) L. K. Fung et al. PEDIATRICS
- Predictors of placebo response in pharmacological and dietary supplement treatment trials in pediatric autism spectrum disorder: a meta-analysis
- (2015) A Masi et al. Translational Psychiatry
- Oxytocin-Mediated GABA Inhibition During Delivery Attenuates Autism Pathogenesis in Rodent Offspring
- (2014) R. Tyzio et al. SCIENCE
- GABAergic Signaling as Therapeutic Target for Autism Spectrum Disorders
- (2014) Giada Cellot et al. Frontiers in Pediatrics
- P-640 - The power of expectation bias
- (2012) J.B. Williams et al. EUROPEAN PSYCHIATRY
- Effects of STX209 (Arbaclofen) on Neurobehavioral Function in Children and Adults with Fragile X Syndrome: A Randomized, Controlled, Phase 2 Trial
- (2012) E. M. Berry-Kravis et al. Science Translational Medicine
- A randomised controlled trial of bumetanide in the treatment of autism in children
- (2012) E Lemonnier et al. Translational Psychiatry
- Therapeutic Strategies in Fragile X Syndrome: Dysregulated mGluR Signaling and Beyond
- (2011) Christina Gross et al. NEUROPSYCHOPHARMACOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started